Noxa is a BH3-only member of the Bcl-2 family, upregulated by p53 as a response to DNA damage. Mutations in the BH3-only region of other BH3-only members lead to an inactive protein. We have investigated the mRNA expression of Noxa with real-time PCR in 94 unselected colorectal adenocarcinomas and the corresponding normal mucosa. Among them, Noxa protein expression was investigated with immunohistochemistry in 16 tumors and six corresponding normal mucosa samples. Further, we searched for Noxa mutations in all the cases using single-stranded conformation polymorphism and DNA sequencing. The mRNA expression of Noxa was weak in 9% and strong in 2% of the tumors, and decreased in 9% and increased in 16% of the tumors compared with the normal mucosa; however, these changes did not have any clinical or pathological significance. The protein level in most of the cases investigated was correlated with the mRNA level. We did not find any mutations in the Noxa gene. Thus, we suggest that Noxa may not be of importance in the development of colorectal cancer.
The Bcl-2 family plays an important role in regulating the mitochondrial pathway for apoptosis. The family consists of proteins that inhibit or promote apoptosis and variably contains homology domains BH1, BH2, BH3 and BH4.
Bax is a proapoptotic member of the Bcl-2 family, and an effector of p53. The expression of Bax is induced as one of the responses to DNA damage (Hengartner, 2000) . In Bax-deficient mice and embryonic fibroblasts, DNA damage-induced apoptosis occurs (McCurrach et al., 1997; Shibata et al., 1999) . Therefore, the existence of at least one other target gene appears necessary to explain the p53-dependent apoptosis. The Noxa gene was found by Oda et al. (2000a) after X-ray irradiation of mouse embryo fibroblasts as a response to DNA damage and was upregulated by p53. Noxa is a member of proapoptotic BH3-only proteins in the Bcl-2 family. The human gene is located to chromosome 18q21 and encodes a 54-amino-acid protein containing one BH3 motif. In the promoter of Noxa, there is one p53 recognition site (Oda et al., 2000a) . In members of the BH3-only proteins such as Bid, Bad and Noxa, mutations in the BH3 domain leads to an inactive protein (Zha et al., 1997; Wei et al., 2000) . Deregulation of apoptosis plays an important role in tumor development. The p53 gene is mutated in about 50% of colorectal tumors and its overexpression is associated with worse survival (Sun et al., 1992; Jansson et al., 2001) . Bax mutations have been detected in leukemias, gastrointestinal and colorectal cancer (Rampino et al., 1997; Zhang et al., 2000) . Abrogation in Bax and Bak protein expression has been observed in skin, gastric and colorectal cancer (Rosen et al., 1998; Jackson et al., 2000) . Deregulation in the p53 pathway seems to be an important target in the development of colorectal cancer, and it is of great interest to investigate whether mutations in Noxa are present in colorectal cancer, and whether the levels of mRNA and protein expression are of importance. This is the first study that has investigated the importance of the Noxa gene in a series of human tumors. In the present study, we used real-time PCR to investigate Noxa mRNA expression, immunohistochemistry to determine protein expression, and DNA sequencing to detect mutation in the Noxa gene. The study included primary tumors and the corresponding normal mucosa samples from 94 patients with colorectal adenocarcinoma. We wanted to identify whether low Noxa level in the tumor or changed levels from normal mucosa to tumors had clinical and pathological significance regarding patients' sex, age, tumor location, Dukes' stage, growth pattern, differentiation and prognosis.
The level of Noxa in the tumor and the corresponding normal mucosa was examined as a quota between the mRNA expression of Noxa and the endogenous control gene phosphoglycerate kinase (PGK). Noxa mRNA expression was found in all the 94 tumors and the corresponding normal mucosa. The quota between Noxa and PGK mRNA expression in the tumor ranged from 0.05 to 3.92, mean 0.66 and median 0.64 (Figure 1 ). Respective weak and strong expression was considered as four times more or less Noxa mRNA than the mean, and the remaining cases were scored as moderate expression. Eight tumors (9%) showed weak expression, two (2%) showed strong expression and 84 (89%) showed moderate expression. There was no association between the level of mRNA expression in the tumor and patients' sex, age, tumor location, Dukes' stage, growth pattern, differentiation (Table 1) or prognosis. The quota between Noxa and PGK mRNA expression in the tumor divided by the quota between Noxa and PGK mRNA expression in the corresponding normal mucosa ranged from 0.03 to 34.05, mean 2.9 and median 1.2 ( Figure 1 ). Respective increased or decreased level was judged as four times more or less expression in the tumor compared with the corresponding normal mucosa. Nine patients (9%) had decreased expression, 15 (16%) had increased expression and 70 (75%) showed the same expression in the tumor as in the normal mucosa. There was no association between the changes in Noxa mRNA expression in the tumor compared to the normal mucosa and patients' sex, age, tumor location, Dukes' stage, growth pattern, differentiation (Table 1) or prognosis. Further, we even used a cutoff value of two times more or less expression and a continuous variable of Noxa values, but failed to find relation to clinicopathological variables. It is difficult to speculate about the influence of Noxa on survival due to the short follow-up period. The upregulation of Noxa in some tumors may be a response to DNA damage, and the downregulation may be a sign of mutations in the p53 gene.
Among the 94 cases, Noxa protein expression was investigated in 16 tumors and six corresponding normal mucosa samples. The specificity of the Noxa antibody was determined with Western blot (Figure 2) . A total of 13 tumors showed both nuclear and cytoplasmic expression, two showed nuclear expression alone and one showed cytoplasmic expression alone. With respect to the staining intensity, the tumors were divided into three groups: three (19%) showed weak expression, nine (56%) moderate expression and four (25%) strong expression (Figure 3) . In all, 10 out of 16 tumors showed that the levels of the protein were correlated with the measurement of Noxa mRNA, that is, weak staining with decreased mRNA, moderate with unchanged mRNA and strong with increased mRNA. Four tumors had weaker protein expression compared with mRNA expression and the other two, vice versa. With respect to the protein expression in the normal mucosa, three out of six showed expression correlated with the mRNA measurement. The diverse results between the two methods may result from heterogenity of the protein expression in the tissue. For example, we did find some cases that showed strong protein expression in a small area of the section. In such cases, the levels of mRNA expression were diluted and might have been underevaluated when mRNA was measured. Besides, it is possible that mRNA or protein was degraded during storage.
In cell culture studies, mutations in the BH3 region of BH3-only family members lead to a nonfunctional protein (Zha et al., 1997; Wei et al., 2000) , indicating that this region may be a sensitive target in tumor development. Studies on the Bax gene have shown that mutations are of importance in the development of skin, gastrointestinal and colorectal cancer (Rampino et al., 1997; Zhang et al., 2000) . We performed SSCP-DNA The w 2 method or Fishers' test was used to test the association of Noxa expression in the tumors or the tumors compared with the normal mucosa with clinicopathological factors. All P-values that are cited are two-sided, and the P-values that were less than 5% were deemed statistically significant sequencing in all the tumors and the corresponding normal mucosa, but did not find any mutations in the BH3 region or elsewhere in the Noxa gene. Our result implies that neither the BH3 region nor the rest of the Noxa gene was a target in the tumor development of colorectal cancer.
Several members of the Bcl-2 family subgroup of BH3-only proteins have similar functions, but the exact mechanisms are unclear. The members do not act independently and require multidomain proapoptotic Bcl-2 family members to induce apoptosis (Huang and Strasser, 2000) . Noxa is upregulated by p53, and other members of the Bcl-2 family that are also upregulated by the same pathway. The redundancy of many of the BH3-only members may be one reason why we did not find that the changes in Noxa expression were of importance in colorectal cancer.
After the finding of Noxa, it was discovered that two new genes were upregulated by p53: p53 upregulated Figure 1 The quota between Noxa and PGK mRNA expression in the tumor as well as the quota between Noxa and PGK mRNA expression in the tumor divided by the quota between Noxa and PGK mRNA expression in the corresponding normal mucosa determined with real-time PCR for each case. The study included frozen tumors and the corresponding normal mucosa samples from 94 patients, who underwent surgical resection for colorectal cancer, diagnosed at the Vrinnevi Hospital, Norrko¨ping, Sweden, between 1991 and 2000. The mean age was 74 years (range 49-96). To quantify the amount of mRNA in the tumor and the corresponding normal mucosa, we employed real-time PCR, described by Heid et al. (1996) . Total RNA was extracted using the SV Total RNA Isolation System (Promega, Madison, WI, USA), and synthesis of cDNA from total RNA was performed using the first-strand cDNA Synthesis Kit with random hexameres (Roche Diagnostics Corporation, Indianapolis, IN, USA). The designed forward and reverse and fluorescently marked probe used for the Noxa gene in the assay were 5 0 -TGGAAGTCGAG TGTGCTACTCAA, 5 0 -CAGAAGAGTTTGGATATCAGATT-CAGA, and 5 0 -FAM-TTTCTGCCGGAAGTTCAGTTTGTCTC-CAA-TAMRA. A standard curve for Noxa and PGK was run on each plate, using serial diluted cDNA from normal colon (Stratagene, Cedarcreek, TX, USA) to normalize the runs. All samples were run as triplicates, and in all experiments samples without template were used as control. The relative quantification of the Noxa gene was performed according to the manufacturer's description (Protocol P/N 4303859, Perkin-Elmer). The PCR-SSCP reaction was performed as described previously (Jansson and Sun, 2002) with the following outer and inner primers; outer reverse and forward 5 0 -GTCCGAGGTGCTCCAGTT, 5 0 -AAACGTGCAC CTCCTGAGA, inner reverse and forward 5 0 -GGGCTCTGT CGCTGAG, 5 0 -TGCACCTCCTGAGAAAACT Figure 3 Immunohistochemical analysis of the Noxa protein in tumors and normal mucosa (magnification Â 200): (a) weak protein expression in the nucleus and cytoplasm, the case was identified as moderate mRNA expression; (b) Moderate protein expression in the nucleus and cytoplasm, the case was identified as moderate mRNA expression; (c) strong protein expression in the cytoplasm, the case was identified as strong mRNA expression; (d) weak protein expression in the nucleus in normal mucosa, the case was identified as weak mRNA expression; (e) a tumor sample as negative control. Immunohistochemistry was performed as previously described (Jansson and Sun, 2002) on 5 mm sections from paraffin-embedded material with a monoclonal antibody against Noxa (OP180, Oncogene Science, USA), in 1 : 50 for 2 h. The slides were treated in a pressure cooker for 10 min in 0.01 m Tris-EDTA buffer (pH 9.0). The antibody was visualized using the Dako ChemMate EnVision Detection kit (Dako, Denmark) and counterstained with hematoxylin. Sections known to stain positively were included in each run with isotype IgG1 as negative control modulator of apoptosis (PUMA) (Nakano and Vousden, 2001 ) and p53AIP1 (Oda et al., 2000b) . PUMA was shown to be a new member of the BH3-only family. In colorectal cell lines, PUMA was found to be more important than Noxa in the p53-dependent apoptosis (Yu et al., 2001 ). This may be another reason why we did not find that alteration in Noxa mRNA expression was of importance in the present group of the patients.
In conclusion, Noxa was expressed in all normal colorectal mucosa and cancer samples. The expression was up-or downregulated in a fraction of the cases, but the changes did not have any clinical or pathological significance. Further, we did not find any mutations in the Noxa gene. Thus, these observations suggest that changes in Noxa expression may not be of particular importance in the development of unselected colorectal cancer.
